FindTrial
Sign In

Application of metformin in treatment of non-dementia vascular cognitive impairment

Application of metformin in treatment of non-dementia vascular cognitive impairment

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-17011855
Enrollment
Unknown
Registered
2017-07-04
Start date
2017-07-04
Completion date
Unknown
Last updated
2017-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vascular cognitive impairment

Interventions

metformin group:metformin and donepezil,
acarbose group:acarbose and donepezil

Sponsors

Tianjin First Center Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: OGTT shows abnormal glucose metabolism;patients have symptom or evidence of cognitive impairment; do not meet the diagnostic criteria of dementia in DSM-IV; CDR= 0.5; MMSE 26-27 to 17-24; ADAS-Cog=10; ADL=26

Exclusion criteria

Exclusion criteria: MMSE=16,any significant cardiovascular or pulmonary or hepatic or renal disease,Thyroid dysfunction, lower than a primary school education level.

Design outcomes

Primary

MeasureTime frame
MoCA score;—

Secondary

MeasureTime frame
fasting insulin;insulin resistance index;glycosylated hemoglobin A1c;fasting plasma glucose;—

Countries

China

Contacts

Public ContactMa Chunchao

Tianjin First Center Hospital

13752451956@163.com+86 13752451956

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 23, 2026